NICE has recommended further evidence generation for the Genedrive MT-RNR1 ID Kit, a technology developed to detect a genetic variant that guides antibiotic use and prevents hearing loss in babies.
This plan outlines the gaps in evidence for the technology and the real-world data that needs to be collected for a future NICE review. The responsibility for data collection and analysis lies with the technology developer.
Support for evidence generation will be facilitated by the Office for Life Sciences, pending business case approval. This includes funding for evidence generation consortia, bringing together analytical partners, implementation sites, and developers.
Guidance on commissioning and procurement of the technology will be provided by NHS England, who is also developing a digital health technology policy framework.
After 3 years of evidence generation, the developer should submit the evidence to NICE for review and decision making on routine adoption in the NHS.
From Skepticism to Support: Healthcare Providers’ Acceptance of Digital Interventions in SUD Treatment in Kenya💡
Healthcare providers in Kenya show high acceptance of digital interventions for substance use disorder treatment. Learn more about how technology is shaping healthcare delivery.
#SyenzaNews #HealthcareInnovation #DigitalInterventions #SubstanceUseDisorder #KenyaHealthcare 🏥💻
📢 #SyenzaNews: The FDA is modernising regulations for AI medical devices with a firm-based approach. This shift focuses on the quality systems of manufacturing firms rather than individual product mechanics.
Discover how this new method can enhance safety and foster innovation in healthcare.
Read more here.
#LifeSciences #HealthcareInnovation #AIMedicalDevices #FDARegulations #HealthTech
Abu Dhabi is making remarkable progress in healthcare through strategic partnerships with leading institutions like CHOP and Penn Medicine. These collaborations aim to advance paediatric oncology, gene therapy, and translational research. 🌍💉
#SyenzaNews #HealthcareInnovation #PaediatricOncology #GeneTherapy #TranslationalResearch #AbuDhabiHealthcare
Read more about how these partnerships are set to transform healthcare in Abu Dhabi and beyond.
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
